Guidance for Cyrusone (CONE)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2021 | $4.03 – $4.08 | N/A | $1.18B – 1.20B | $1.17B | = Maintained | Details |
| 2021 | $3.95 – $4.05 | N/A | $1.16B – 1.19B | $1.15B | = Maintained | Details |
| 2021 | $3.90 – $4.00 | N/A | $1.14B – 1.18B | $1.13B | = Maintained | Details |
| 2021 | $3.90 – $4.00 | N/A | $1.11B – 1.15B | $1.12B | = Maintained | Details |
| 2020 | $3.75 – $3.90 | N/A | $1.01B – 1.05B | N/A | = Maintained | Details |
| 2020 | N/A | N/A | $1.01B – 1.05B | $1.04B | = Maintained | Details |
| 2019 | $3.55 – $3.60 | N/A | $970.00M – 980.00M | N/A | = Maintained | Details |
| 2019 | $3.50 – $3.60 | N/A | $970.00M – 990.00M | $970.83M | = Maintained | Details |
| 2019 | $3.30 – $3.40 | $3.18 | $960.00M – 1000.00M | $977.60M | = Maintained | Details |
| 2018 | N/A | N/A | $810.00M – 825.00M | $796.95M | = Maintained | Details |
| Q4 2018 | $3.25 – $3.30 | $3.28 | N/A | N/A | = Maintained | Details |
| Q3 2018 | $3.25 – $3.30 | N/A | $820.00M – 830.00M | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2017 | $3.00 – $3.10 | $3.10 | $666.00M – 681.00M | $674.00M | = Maintained | Details |
| 2017 | $2.95 – $3.05 | $2.92 | N/A | N/A | = Maintained | Details |
| Q4 2017 | $3.05 – $3.10 | N/A | $670.00M – 677.00M | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2016 | $2.50 – $2.58 | N/A | N/A | N/A |  Raised |
Details |
| 2015 | $2.11 – $2.15 | $2.10 | N/A | N/A | Raised |
Details |
| 2015 | $2.07 – $2.13 | $2.01 | $398.00M – 404.00M | $389.90M | = Maintained | Details |
| 2014 | N/A | N/A | $305.00M – 315.00M | $310.68M | = Maintained | Details |
| 2013 | $1.15 – $1.25 | N/A | $260.00M – 270.00M | N/A | = Maintained | Details |
